Autologous bone marrow mononuclear cell transplantation

Phase 1Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 11/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Dec 1, 2008 → Jan 1, 2014

NCT ID

NCT02065778

About Autologous bone marrow mononuclear cell transplantation

Autologous bone marrow mononuclear cell transplantation is a phase 1 stage product being developed by Brain Biotech for Cerebrovascular Accident. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02065778. Target conditions include Cerebrovascular Accident.

What happened to similar drugs?

5 of 7 similar drugs in Cerebrovascular Accident were approved

Approved (5) Terminated (1) Active (1)

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved

✅AtorvastatinPfizerApproved

✅Botulinum toxin type A + PlaceboIpsenApproved

✅Atorvastatin 20mgBrain BiotechApproved

🔄donepezil hclEisaiPhase 3

❌AbciximabEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02009124	Phase 2	Withdrawn	Aug 1, 2012	Dec 1, 2018	Spinal Cord Injury
NCT02028104	Phase 1	Withdrawn	Jan 1, 2010	Sep 1, 2016	Traumatic Brain Injury
NCT02027246	Phase 1	Withdrawn	Dec 1, 2008	Feb 1, 2013	Spinal Cord Injury
NCT02050776	Phase 1	Withdrawn	Dec 1, 2008	Dec 1, 2013	Limb Girdle Muscular Dystrophy
NCT02065778	Phase 1	Withdrawn	Dec 1, 2008	Jan 1, 2014	Cerebrovascular Accident

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	35
donepezil hcl	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43
ONO-2506	Ono Pharmaceutical	Phase 2/3	30
Abciximab	Eli Lilly	Phase 3	32
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	26
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	43
Valsartan	Novartis	Pre-clinical	18
Atorvastatin	Pfizer	Approved	43
Rivaroxaban	Bayer	Pre-clinical	19
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	26
Botulinum toxin type A + Placebo	Ipsen	Approved	40
Atorvastatin 20mg	Brain Biotech	Approved	40
Roflumilast Oral Tablet	Brain Biotech	Phase 2	25